US 12,274,683 B2
Topical gel compositions of naproxen
Olufoyekemi Badejo, Bridgewater, NJ (US)
Assigned to Bayer HealthCare LLC, Indianola, PA (US)
Appl. No. 17/425,746
Filed by Bayer HealthCare LLC, Indianola, PA (US)
PCT Filed Jan. 8, 2020, PCT No. PCT/US2020/012654
§ 371(c)(1), (2) Date Jul. 26, 2021,
PCT Pub. No. WO2020/159676, PCT Pub. Date Aug. 6, 2020.
Claims priority of provisional application 62/798,352, filed on Jan. 29, 2019.
Prior Publication US 2022/0160667 A1, May 26, 2022
Int. Cl. A61K 31/192 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/18 (2017.01); A61K 47/32 (2006.01); A61K 47/38 (2006.01); A61P 29/00 (2006.01)
CPC A61K 31/192 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/183 (2013.01); A61K 47/32 (2013.01); A61K 47/38 (2013.01); A61P 29/00 (2018.01)] 29 Claims
OG exemplary drawing
 
1. A topical gel composition, comprising:
the ammonium salt of naproxen;
one or more gelling agents; and
water,
wherein the one or more gelling agents comprise hydroxyethylcellulose,
wherein the topical gel composition comprises propylene glycol and polyethylene glycol, and
wherein the topical gel composition has a total concentration of naproxen of at least 1% w/w.